# BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Source: https://onco.cc/trials/nct07193511/  
OnCo record `nct07193511` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AVZO-103 in bladder & urothelial cancer, run by Avenzo Therapeutics, Inc., now recruiting.

## Summary

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001). ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 355 participants. Primary completion is estimated at 2030-03. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AVZO-103, Combination Agent. Registered primary measures: Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1); Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1); Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: BEACON-1
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07193511
- Phase: 1/2
- Setting: BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- Sponsor: Avenzo Therapeutics, Inc.
- Enrolled: 355

## Notes

- ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 355 participants. Primary completion is estimated at 2030-03. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT07193511: https://clinicaltrials.gov/study/NCT07193511

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/)
- drugs: [AVZO-103](https://onco.cc/drugs/avzo-103/)

---
JSON: https://onco.cc/api/v1/entities/nct07193511.json